Search Within

Karen Anne Autio

Formats
  1. Meeting Abstract (77)
  2. Journal Article (40)
  3. Review (3)
Groups
  1. Department of Medicine (120)
  2. Genitourinary Oncology Service (120)
  3. Solid Tumor Oncology Division (120)
  4. Hematologic Malignancies, Division of (30)
  5. GSK Faculty (21)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Howard Scher (46)
  2. Michael Morris (36)
  3. Dana Rathkopf (34)
  4. Susan Slovin (28)
  5. Daniel Danila (22)
  6. Wassim Abida (15)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (7)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (48)
  2. Annals of Oncology (18)
  3. Journal for ImmunoTherapy of Cancer (11)
  4. Clinical Cancer Research (8)
  5. Journal of Immunotherapy and Precision Oncology (3)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (50)
  2. Oxford University Press (18)
  3. Biomed Central Ltd (11)
  4. American Association for Cancer Research (10)
  5. Elsevier Inc. (5)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (120)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
    Meeting Abstract

    Hecht, J. R.; Naing, A.; Falchook, G.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K.; Wainberg, Z. A.; Javle, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Immunologic and objective tumor responses to PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)
    Meeting Abstract

    Randolph, H. J.; Aung, N.; Gerald, F.; Manish, P.; Jeffrey, I.; Raid, A.; Wong, D.; Karen, A.; Zev, W.; Milind, J.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Evaluation of histological changes in radical prostatectomy (RP) after neoadjuvant androgen deprivation therapy (NeoADT): Comparison between conventional and newer therapy regimens
    Meeting Abstract

    Huang, K. C.; Mirsadraei, L.; Chen, Y. B.; Sirintrapun, J. S.; Al-Ahmadie, H.; Fine, S. W.; Touijer, K. A.; Eastham, J.; Autio, K. A.; Rathkopf, D. E.; more...
    Modern Pathology (2017)

    Fulltext@MSK | Save
  • Evaluation of histological changes in radical prostatectomy (RP) after neoadjuvant androgen deprivation therapy (NeoADT): Comparison between conventional and newer therapy regimens
    Meeting Abstract

    Huang, K. C.; Mirsadraei, L.; Chen, Y. B.; Sirintrapun, J. S.; Al-Ahmadie, H.; Fine, S. W.; Touijer, K. A.; Eastham, J.; Autio, K. A.; Rathkopf, D. E.; more...
    Laboratory Investigation (2017)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer
    Meeting Abstract

    Papadopoulos, K. P.; Naing, A.; Infante, J. R.; Autio, K. A.; Ott, P. A.; Wong, D. J. L.; Falchook, G. S.; Patel, M. R.; Pant, S.; Whiteside, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Infante, J. R.; Wong, D. J. L.; Autio, K. A.; Ott, P. A.; Falchook, G. S.; Patel, M. R.; Pant, S.; Patnaik, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    Infante, J. R.; Ahlers, C. M.; Hodi, F. S.; Postel-Vinay, S.; Schellens, J. H. M.; Heymach, J.; Autio, K. A.; Barnette, M. S.; Struemper, H.; Watmuff, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save